Metformin use in the prevention of gestational diabetes in obese nondiabetic pregnant women: an evidence-based review
DOI:
https://doi.org/10.32385/rpmgf.v38i1.13128Keywords:
Pregnancy, Obesity, Metformin, Diabetes, GestationalAbstract
Objectives: To clarify the role of metformin in the prevention of gestational diabetes in obese non-diabetic pregnant women.
Data sources: The Cochrane Library, Canadian Medical Association Infobase, Database of Abstracts of Reviews of Effects, NICE Guidelines Finder, National Guideline Clearinghouse, BMJ Clinical Evidence, PubMed, and Portuguese Medical Journals Index.
Review methods: In June 2020, we searched for meta-analysis, systematic reviews, controlled and randomized clinical trials and clinical guidelines published between May 2010 and May 2020, in Portuguese and English. The searched MeSH terms were: Pregnancy, Obesity, Metformin, Diabetes Gestational and the terms Health Sciences Descriptors ‘Gravidez’, ‘Obesidade’, ‘Metformina’, ‘Diabetes gestacional’. We used the American Family Physician's Strength Of Recommendation Taxonomy (SORT) scale to classify the evidence.
Results: The search provided 152 articles, of which three met the inclusion criteria and were selected. A 2018 Cochrane review, based on three randomized and randomized controlled trials (ECAC) with a total of 1,099 pregnant women, found no differences in the rate of gestational diabetes in the metformin vs. placebo groups (level of evidence 1). A meta-analysis by Chatzakis et al. evaluated four ECAC, including 624 women, and concluded that metformin does not diminish the risk of developing gestational diabetes (level of evidence 1). Sales et al. included 164 pregnant women (82 metformin vs 82 control) and concluded that the use of metformin is not effective in preventing gestational diabetes (level of evidence 2).
Conclusions: There is no available evidence to recommend metformin use for GD prevention in obese pregnant women (strength of recommendation A).
Downloads
References
Sales WB, Nascimento IB, Dienstmann G, Souza ML, Silva GD, Silva JC. Effectiveness of metformin in the prevention of gestational diabetes mellitus in obese pregnant women. Rev Bras Ginecol Obstet. 2018;40(4):180-7.
Barreto M, Gaio V, Kislaya I, Antunes L, Rodrigues AP, Silva AC, et al. 1º Inquérito nacional de saúde com exame físico (INSEF 2015): estado de saúde [homepage]. Lisboa: Instituto Nacional de Saúde Dr. Ricardo Jorge; 2016. Available from: http://www2.insa.pt/sites/INSA/Portugues/ComInf/Noticias/Paginas/1INSEFrelat%C3%B3rio.aspx
Dodd JM, Louise J, Deussen AR, Grivell RM, Dekker G, McPhee AJ, et al. Effect of metformin in addition to dietary and lifestyle advice for pregnant women who are overweight or obese: the GRoW randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;7(1):15-24.
Raposo JF. Diabetes: factos e números 2016, 2017 e 2018. Rev Port Diabetes. 2020;15(1):19-27.
Chatzakis C, Goulis DG, Mareti E, Eleftheriades M, Zavlanos A, Dinas K, et al. Prevention of gestational diabetes mellitus in overweight or obese pregnant women: a network meta-analysis. Diabetes Res Clin Pract. 2019;158:107924.
Almeida M, Dores J, Ruas L. Consenso Diabetes Gestacional: atualização 2017 [Consensus on gestational diabetes: 2017 update]. Rev Port Diabetes. 2017;12(1):24-38. Portuguese
Williams T, Mortada R, Porter S. Diagnosis and treatment of polycystic ovary syndrome. Am Fam Physician. 2016;94(2):106-13.
Dodd JM, Grivell RM, Deussen AR, Hague WM. Metformin for women who are overweight or obese during pregnancy for improving maternal and infant outcomes. Cochrane Database Syst Rev. 2018;7(7):CD010564.
Ebell MH, Siwek J, Weiss BD, Woolf SH, Susman J, Ewigman B, et al. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. Am Fam Physician. 2004;69(3):548-56.
Syngelaki A, Nicolaides KH, Balani J, Hyer S, Akolekar R, Kotecha R, et al. Metformin versus placebo in obese pregnant women without diabetes mellitus. N Engl J Med. 2016;374(5):434-43.
Chiswick C, Reynolds RM, Denison F, Drake AJ, Forbes S, Newby DE, et al. Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2015;3(10):778-86.
El Fattah EA. Can metformin limit weight gain in the obese with pregnancy? Int J Reprod Contracept Obstet Gynecol. 2016;5(3):818-25.
World Health Organization. Diagnostic criteria and classification of hyperglycaemia first detected in pregnancy [homepage]. Geneva: World Health Organization; 2013. Available from: https://apps.who.int/iris/handle/10665/85975
Brink HS, Alkemade M, van der Lely AJ, van der Linden J. Metformin in women at high risk of gestational diabetes mellitus. Diabetes Metab. 2018;44(3):300-2.
O'Connor DL, Blake J, Bell R, Bowen A, Callum J, Fenton S, et al. Canadian consensus on female nutrition: adolescence, reproduction, menopause, and beyond. J Obstet Gynaecol Can. 2016;38(6):508-54.e18.
Harrison CL, Brown WJ, Hayman M, Moran LJ, Redman LM. The role of physical activity in preconception, pregnancy and postpartum health. Semin Reprod Med. 2016;34(2):e28-37.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Portuguese Journal of Family Medicine and General Practice
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The authors will assign to the RPMGF the sole right to publish and distribute the content of the manuscript specified in this declaration via physical, electronic, broadcasting or any other medium that may come into existence. They also grant the RPMGF the right to use and exploit this manuscript, in particular by assigning, selling or licensing its content. This permission is permanent and takes effect from the moment the manuscript is submitted, has the maximum duration allowed by applicable Portuguese or international law and is of worldwide scope. The authors further declare that this assignment is made free of charge. If the RPMGF informs the authors that it is not going to publish their manuscript, the exclusive assignment of rights ceases forthwith.
The authors authorise the RPMGF (or any entity it may appoint) to act on their behalf when it believes that copyright may have been infringed.
